Ruxolitinib Combined with Gemcitabine against Cholangiocarcinoma Growth via the JAK2/STAT1/3/ALDH1A3 Pathway
Sign Up to like & getrecommendations! Published in 2021 at "Biomedicines"
DOI: 10.3390/biomedicines9080885
Abstract: Cholangiocarcinoma is the most common primary malignant tumor of the bile duct. The current standard first-line treatment for advanced or metastatic cholangiocarcinoma is gemcitabine and cisplatin. However, few effective treatment choices exist for refractory cholangiocarcinoma,… read more here.
Keywords: jak2 stat1; cholangiocarcinoma; combined gemcitabine;
Immunomodulatory antitumor effect of interferon‑beta combined with gemcitabine in pancreatic cancer.
Sign Up to like & getrecommendations! Published in 2022 at "International journal of oncology"
DOI: 10.3892/ijo.2022.5387
Abstract: Resistance to gemcitabine is common and critically limits its therapeutic efficacy in patients with pancreatic cancer. Interferon‑beta (IFN‑β) induces numerous antitumor effects and synergizes with gemcitabine treatment. The immunomodulatory effects of this treatment regimen have… read more here.
Keywords: pancreatic cancer; antitumor effect; combined gemcitabine; interferon beta ... See more keywords